Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER


Journal

BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723

Informations de publication

Date de publication:
08 Oct 2024
Historique:
received: 14 02 2024
accepted: 30 09 2024
medline: 9 10 2024
pubmed: 9 10 2024
entrez: 8 10 2024
Statut: epublish

Résumé

Increased levels of physical activity are associated with a reduction of breast cancer mortality, especially in postmenopausal women with positive hormone receptor status. So far, previous observational case-control and cohort studies have focused on associations between overall leisure time physical activity and survival of women with breast cancer in general. In this multicenter prospective cohort study, conducted in Germany between 30th August 2012 to 29th December 2017, we investigated general physical activity in a homogenous sample of n = 1440 postmenopausal women with advanced (inoperable locally advanced or metastatic), hormone receptor-positive breast cancer receiving the same therapy (everolimus and exemestane). Self-reported physical activity was assessed using the Godin Leisure Time Exercise Questionnaire (GLTEQ) before and every 3 months during treatment. Participants were then classified into "active" and "insufficiently active" to screen their activity behavior the week prior to medical treatment. In addition, changes in physical activity patterns were assessed. Adjusted Cox regression analyses were performed for the activity categories to determine hazard ratios (HR). Besides progression-free survival (PFS), adverse events (AEs), QoL, and fatigue were assessed every 3 months until study termination. Compared to "insufficiently active" patients, "active" individuals indicated a significantly longer PFS (HR: 0.84 [0.74; 0.984], p = .0295). No significant differences were observed for changes of physical activity behavior. Patients who reported to be "active" at baseline revealed significantly fewer AEs compared to "insufficiently" active patients. In detail, both severe and non-severe AEs occurred less frequently in the "active" patients group. In line with that, QoL and fatigue were better in physical "active" patients compared to their insufficient active counterparts at the last post-baseline assessment. Participants who remained or become active indicated less AEs, a higher QoL, and reduced fatigue levels. Physical activity behavior prior to medical treatment might have prognostic value in patients with advanced breast cancer in terms of extending the PFS. Moreover, physical activity before and during treatment may reduce treatment-related side effects and improve patients' QoL and fatigue. EUPAS9462. Registered 30th October 2012 "retrospectively registered."

Sections du résumé

BACKGROUND BACKGROUND
Increased levels of physical activity are associated with a reduction of breast cancer mortality, especially in postmenopausal women with positive hormone receptor status. So far, previous observational case-control and cohort studies have focused on associations between overall leisure time physical activity and survival of women with breast cancer in general.
METHODS METHODS
In this multicenter prospective cohort study, conducted in Germany between 30th August 2012 to 29th December 2017, we investigated general physical activity in a homogenous sample of n = 1440 postmenopausal women with advanced (inoperable locally advanced or metastatic), hormone receptor-positive breast cancer receiving the same therapy (everolimus and exemestane). Self-reported physical activity was assessed using the Godin Leisure Time Exercise Questionnaire (GLTEQ) before and every 3 months during treatment. Participants were then classified into "active" and "insufficiently active" to screen their activity behavior the week prior to medical treatment. In addition, changes in physical activity patterns were assessed. Adjusted Cox regression analyses were performed for the activity categories to determine hazard ratios (HR). Besides progression-free survival (PFS), adverse events (AEs), QoL, and fatigue were assessed every 3 months until study termination.
RESULTS RESULTS
Compared to "insufficiently active" patients, "active" individuals indicated a significantly longer PFS (HR: 0.84 [0.74; 0.984], p = .0295). No significant differences were observed for changes of physical activity behavior. Patients who reported to be "active" at baseline revealed significantly fewer AEs compared to "insufficiently" active patients. In detail, both severe and non-severe AEs occurred less frequently in the "active" patients group. In line with that, QoL and fatigue were better in physical "active" patients compared to their insufficient active counterparts at the last post-baseline assessment. Participants who remained or become active indicated less AEs, a higher QoL, and reduced fatigue levels.
CONCLUSIONS CONCLUSIONS
Physical activity behavior prior to medical treatment might have prognostic value in patients with advanced breast cancer in terms of extending the PFS. Moreover, physical activity before and during treatment may reduce treatment-related side effects and improve patients' QoL and fatigue.
TRIAL REGISTRATION BACKGROUND
EUPAS9462. Registered 30th October 2012 "retrospectively registered."

Identifiants

pubmed: 39379960
doi: 10.1186/s12916-024-03671-x
pii: 10.1186/s12916-024-03671-x
doi:

Substances chimiques

exemestane NY22HMQ4BX
Androstadienes 0
Everolimus 9HW64Q8G6G
Receptors, Estrogen 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

442

Informations de copyright

© 2024. The Author(s).

Références

Schmid D, Leitzmann MF. Cardiorespiratory fitness as predictor of cancer mortality: a systematic review and meta-analysis. Ann Oncol. 2015;26(2):272–8.
doi: 10.1093/annonc/mdu250 pubmed: 25009011
Schmid D, Leitzmann MF. Association between physical activity and mortality among breast cancer and colorectal cancer survivors: a systematic review and meta-analysis. Ann Oncol. 2014;25(7):1293–311.
doi: 10.1093/annonc/mdu012 pubmed: 24644304
Friedenreich CM, Stone CR, Cheung WY, Hayes SC. Physical activity and mortality in cancer survivors: A systematic review and meta-analysis. JNCI Cancer Spectr. 2019;4(1):pkz080. https://doi.org/10.1093/jncics/pkz080 .
Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA. Physical activity and survival after breast cancer diagnosis. J Am Med Assoc. 2005;293(20):2479–86.
doi: 10.1001/jama.293.20.2479
Steindorf K, Schmidt ME, Klassen O, Ulrich CM, Oelmann J, Habermann N, et al. Randomized, controlled trial of resistance training in breast cancer patients receiving adjuvant radiotherapy: results on cancer-related fatigue and quality of life. Ann Oncol. 2014;25(11):2237–43.
doi: 10.1093/annonc/mdu374 pubmed: 25096607
Schmidt ME, Wiskemann J, Armbrust P, Schneeweiss A, Ulrich CM, Steindorf K. Effects of resistance exercise on fatigue and quality of life in breast cancer patients undergoing adjuvant chemotherapy: a randomized controlled trial. Int J Cancer. 2015;137(2):471–80.
doi: 10.1002/ijc.29383 pubmed: 25484317
Buffart LM, Kalter J, Sweegers MG, Courneya KS, Newton RU, Aaronson NK, et al. Effects and moderators of exercise on quality of life and physical function in patients with cancer: an individual patient data meta-analysis of 34 RCTs. Cancer Treat Rev. 2017;52:91–104.
doi: 10.1016/j.ctrv.2016.11.010 pubmed: 28006694
Cormie P, Zopf EM, Zhang X, Schmitz KH. The impact of exercise on cancer mortality, recurrence, and treatment-related adverse effects. Epidemiol Rev. 2017;39(1):71–92.
doi: 10.1093/epirev/mxx007 pubmed: 28453622
Schmidt ME, Chang-Claude J, Vrieling A, Seibold P, Heinz J, Obi N, et al. Association of pre-diagnosis physical activity with recurrence and mortality among women with breast cancer. Int J Cancer. 2013;133(6):1431–40.
doi: 10.1002/ijc.28130 pubmed: 23444048
Zhong S, Jiang T, Ma T, Zhang X, Tang J, Chen W, et al. Association between physical activity and mortality in breast cancer: a meta-analysis of cohort studies. Eur J Epidemiol. 2014;29(6):391–404.
doi: 10.1007/s10654-014-9916-1 pubmed: 24853250
Condorelli R, Vaz-Luis I. Managing side effects in adjuvant endocrine therapy for breast cancer. Expert Rev Anticancer Ther. 2018;18(11):1101–12.
doi: 10.1080/14737140.2018.1520096 pubmed: 30188738
Lüftner D, Schuetz F, Schneeweiss A, Hartkopf A, Bloch W, Decker T, et al. Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: results from the open-label, multicentre, non-interventional BRAWO study. Int J Cancer. 2024;155(1):128–38.
doi: 10.1002/ijc.34912 pubmed: 38447007
Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, Matos L, Gelmon K, Aapro MS, et al. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast. 2024;76:103756.
doi: 10.1016/j.breast.2024.103756 pubmed: 38896983 pmcid: 11231614
Amireault S, Godin G. The godin-shephard leisure-time physical activity questionnaire: validity evidence supporting its use for classifying healthy adults into active and insufficiently active categories. Percept Mot Skills. 2015;120(2):604–22.
doi: 10.2466/03.27.PMS.120v19x7 pubmed: 25799030
Jacobs DR, Ainsworth BE, Hartman TJ, Leon AS. A simultaneous evaluation of 10 commonly used physical activity questionnaires. Med Sci Sport Exerc. 1993;25(1):81–91.
doi: 10.1249/00005768-199301000-00012
Pereira M, Fitzgerald SJ. A collection of physical activity questionnaires for health-related research. Med Sci Sport Exerc. 1997;29(6 Suppl):S1–205.
Organization WH. Guidelines on physical activity and sedentary behaviour. Geneva: World Health Organization; 2020. Available from: https://www.who.int/publications/i/item/9789240015128 .
Osoba D, Zee B, Pater J, Warr D, Kaizer L, Latreille J. Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res. 1994;3(5):353–64.
doi: 10.1007/BF00451727 pubmed: 7841968
Ahmadi MN, Lee IM, Hamer M, del Pozo CB, Chen LJ, Eroglu E, et al. Changes in physical activity and adiposity with all-cause, cardiovascular disease, and cancer mortality. Int J Obes. 2022;46(10):1849–58.
doi: 10.1038/s41366-022-01195-z
Lahart IM, Metsios GS, Nevill AM, Carmichael AR. Physical activity for women with breast cancer after adjuvant therapy. Cochrane Database Syst Rev. 2018;1(1):CD011292. https://doi.org/10.1002/14651858.CD011292.pub2 .
Juvet LK, Thune I, Elvsaas IKØ, Fors EA, Lundgren S, Bertheussen G, et al. The effect of exercise on fatigue and physical functioning in breast cancer patients during and after treatment and at 6 months follow-up: a meta-analysis. Breast. 2017;33:166–77.
doi: 10.1016/j.breast.2017.04.003 pubmed: 28415013
Baumann FT, Reike A, Reimer V, Schumann M, Hallek M, Taaffe DR, et al. Effects of physical exercise on breast cancer-related secondary lymphedema: a systematic review. Breast Cancer Res Treat. 2018;170(1):1–3.
doi: 10.1007/s10549-018-4725-y pubmed: 29470804
Dieli-Conwright CM, Courneya KS, Demark-Wahnefried W, Sami N, Lee K, Sweeney FC, et al. Aerobic and resistance exercise improves physical fitness, bone health, and quality of life in overweight and obese breast cancer survivors: a randomized controlled trial. Breast Cancer Res. 2018;20(1):1–10.
doi: 10.1186/s13058-018-1051-6
Møller T, Andersen C, Lillelund C, Bloomquist K, Christensen KB, Ejlertsen B, et al. Physical deterioration and adaptive recovery in physically inactive breast cancer patients during adjuvant chemotherapy: a randomised controlled trial. Sci Rep. 2020;10(1):1–15.
doi: 10.1038/s41598-020-66513-9
Schumacher O, Luo H, Taaffe DR, Galvão DA, Tang C, Chee R, et al. Effects of exercise during radiation therapy on physical function and treatment-related side effects in men with prostate cancer: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2021;111(3):716–31.
doi: 10.1016/j.ijrobp.2021.06.034 pubmed: 34246737
Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvão DA, Pinto BM, et al. American college of sports medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc. 2010;42(7):1409–26.
doi: 10.1249/MSS.0b013e3181e0c112 pubmed: 20559064
Amireault S, Godin G, Lacombe J, Sabiston CM. Validation of the Godin-Shephard leisure-time physical activity questionnaire classification coding system using accelerometer assessment among breast cancer survivors. J Cancer Surviv. 2015;9(3):532–40.
doi: 10.1007/s11764-015-0430-6 pubmed: 25666749
Godin G, Shephard RJ. A simple method to assess exercise behavior in the community. Can J Appl Sport Sci. 1985;10(3):141–6.
pubmed: 4053261
Lee PH, Macfarlane DJ, Lam T, Stewart SM. Validity of the international physical activity questionnaire short form: a systematic review. Int J Behav Nutr Phys Act. 2011;8(115):1–11.

Auteurs

Philipp Zimmer (P)

Institute for Sport and Sport Science, Division of Performance and Health (Sports Medicine), TU Dortmund University, Dortmund, Germany. philipp.zimmer@tu-dortmund.de.

Tobias Esser (T)

Institute for Sport and Sport Science, Division of Performance and Health (Sports Medicine), TU Dortmund University, Dortmund, Germany.

Diana Lueftner (D)

Immanuel Hospital Märkische Schweiz, AND Medical University of Brandenburg Theodor Fontane, BuckowRüdersdorf Bei Berlin, Germany.

Florian Schuetz (F)

Department of Obstetrics and Gynecology, University Hospital Heidelberg, Heidelberg, Germany.

Freerk T Baumann (FT)

Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.

Achim Rody (A)

Department of Obstetrics and Gynecology, University Hospital Schleswig-Holstein, Lübeck, Germany.

Andreas Schneeweiss (A)

National Center for Tumor Diseases (NCT), Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany.

Andreas D Hartkopf (AD)

Dpt. of Women's Health, University Hospital Tuebingen, Tuebingen, Germany.

Thomas Decker (T)

Medical Center for Hematology and Oncology Ravensburg, Ravensburg, Germany.

Christoph Uleer (C)

Gynecologic Group Practice, Hildesheim, Germany.

Oliver J Stoetzer (OJ)

Medical Center for Hematology and Oncology Munich, Munich, Germany.

Frank Foerster (F)

Poliklinik GmbH Chemnitz, Chemnitz, Germany.

Marcus Schmidt (M)

Dpt. of Obstetrics and Gynecology, Dpt. of Conservative and Molecular Gynecological Oncology, University Medical Center Mainz, Mainz, Germany.

Christoph Mundhenke (C)

Department of Obstetrics and Gynecology, Bayreuth Hospital, Bayreuth, Germany.

Karen Steindorf (K)

German Cancer Research Center, Division of Physical Activity, Prevention and Cancer, Heidelberg, Germany.

Hans Tesch (H)

Center for Hematology and Oncology Bethanien, Frankfurt, Germany.

Christian Jackisch (C)

Dpt. of Obstetrics and Gynecology, Sana Klinikum Offenbach, Offenbach, Germany.

Thomas Fischer (T)

Winicker Norimed GmbH Medical Research, Nuernberg, Germany.

Sven Hanson (S)

Novartis Pharma GmbH, Nuernberg, Germany.

Julia Kreuzeder (J)

Novartis Pharma GmbH, Nuernberg, Germany.

Gernot Guderian (G)

Novartis Pharma GmbH, Nuernberg, Germany.

Peter A Fasching (PA)

Department of Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany.

Wilhelm Bloch (W)

Dpt. for Molecular and Cellular Sports Medicine, German Sport University Cologne, Cologne, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH